Cisplatin or carboplatin for the treatment of non-small cell lung cancer: do they have equivalent efficacy?
Berghmans
T
T
Department of Medicine, Institut Jules Bordet, 1000 Brussels, Belgium.
Paesmans
M
M
Sculier
J P
JP
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology; D002986:Clinical Trials as Topic; D023381:Endpoint Determination; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D012107:Research Design; D016019:Survival Analysis; D013810:Therapeutic Equivalency
D016190:Carboplatin; D002945:Cisplatin